Ashkon Software

   







 


OPXA - Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc. logo Opexa Therapeutics, Inc. (OPXA) was a biopharmaceutical company that focused on developing personalized immunotherapies to treat various autoimmune diseases, including multiple sclerosis (MS). The company's main product candidate was Tcelna, a novel T-cell immunotherapy that aimed to reprogram the immune system to reduce the autoimmune attack on myelin, the protective covering of nerves that is damaged in MS.

Opexa Therapeutics was founded in 2004 and was headquartered in The Woodlands, Texas. The company went public in 2006 and was listed on the NASDAQ stock exchange under the ticker symbol OPXA. However, in May 2018, the company announced that it had completed a reverse merger with Acer Therapeutics, Inc., and the Opexa Therapeutics name and ticker symbol were retired.

At the time of the merger, Opexa Therapeutics had a market capitalization of approximately $17.5 million. The company had no approved products and was heavily dependent on the success of its Tcelna clinical program. The company had conducted several clinical trials to evaluate the safety and efficacy of Tcelna in patients with MS, including a Phase IIb clinical trial called Abili-T.

The Abili-T study enrolled 180 patients with secondary progressive MS and evaluated the safety and efficacy of two different doses of Tcelna compared to placebo. The primary endpoint of the study was the percentage of patients who experienced a confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS). The study did not meet its primary endpoint, as neither dose of Tcelna showed a statistically significant difference compared to placebo.

Despite the disappointing results from the Abili-T study, Opexa Therapeutics continued to explore the potential of Tcelna and other immunotherapies for MS and other autoimmune diseases. The company had a strong intellectual property portfolio and a team of experienced scientists and researchers. However, the company faced significant challenges in securing additional funding to continue its research and development efforts, and the decision to merge with Acer Therapeutics was made in an effort to create a stronger, more financially stable company.

In conclusion, Opexa Therapeutics was a biopharmaceutical company that focused on developing personalized immunotherapies for autoimmune diseases, including MS. The company's main product candidate, Tcelna, did not meet its primary endpoint in a Phase IIb clinical trial, but the company continued to explore the potential of this and other therapies. The company ultimately merged with Acer Therapeutics in 2018 in an effort to create a stronger, more financially stable

 



 

 

 
Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer